Mercury Biopharmaceutical Corporation (6932.TWO)

TWD 13.3

(-2.56%)

Market Cap (In TWD)

5.56 Billion

Revenue (In TWD)

1.03 Million

Net Income (In TWD)

-43.81 Million

Avg. Volume

754.68 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.1-19.75
PE
-
EPS
-
Beta Value
0.0
ISIN
TW0006932007
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yaoren Liang
Employee Count
-
Website
https://merdury.com
Ipo Date
2022-12-23
Details
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic. The company was founded in 2019 and is based in New Taipei City, Taiwan.